The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.
Burisch JDaniel BergemalmJonas HalfvarsonViktor DomislovićZeljko KrznaricAdrian GoldisJens F DahlerupPia OksanenPekka CollinLuisa de CastroVicent HernandezSvetlana TurcanElena BelousovaRenata D'IncàAlessandro SartiniDaniela ValpianiMartina GiannottaRavi MisraNaila ArebiDana DuricovaMartin BortlikKelly GattPierre EllulNatalia PedersenJens KjeldsenKarina W AndersenVibeke AndersenKonstantinos H KatsanosDimitrios K ChristodoulouShaji SebastianLuisa BarrosFernando MagroJóngerð Mm MidjordKári R NielsenRiina SalupereHendrika Al KievitGediminas KiudelisJuozas KupčinskasMathurin FumeryCorinne Gower-RousseauIoannis P KaimakliotisDoron SchwartzSelwyn OdesLaszlo LakatosPeter L LakatosEbbe LangholzPia Munkholmnull nullPublished in: United European gastroenterology journal (2020)
In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.